
    
      The study will comprise:

        -  A screening period of maximum 21 days;

        -  A fixed sequence of 3 treatment periods: Treatment Period 1: Capivasertib only,
           Treatment Period 2: Itraconazole pre-treatment (run-in) period, and Treatment Period 3:
           Capivasertib and itraconazole in combination.

        -  A Follow-up Visit at 7 to 14 days after the last capivasertib PK sample in Treatment
           Period 3.

      There will be no washout between Treatment Period 2 and Treatment Period 3. Each subject will
      be involved in the study for up to 7 weeks.
    
  